Dian Diagnostics Q1 Results Miss Expectations; Goldman Sachs Cuts Target Price to CNY 18

Overview

This report is Goldman Sachs' commentary on Dian Diagnostics' (300244.SZ) Q1 2026 performance. As the company's Q1 revenue and net profit both missed expectations, and the recovery of its Independent Clinical Laboratory (ICL) business was slower than previously assumed, Goldman Sachs has lowered its earnings forecasts for 2026 to 2028. The Sum-of-the-Parts (SOTP) based target price has been cut from CNY 19 to CNY 18, while the 'Neutral' investment rating is maintained. The report notes that while the company faces short-term margin compression and accounts receivable risks, the scaled application of AI business and improved operational efficiency are expected to provide support in the medium to long term.

Core views

Performance vs. Expectations: Dian Diagnostics released its Q1 financial report on April 26, 2026, reporting revenue of CNY 2.247 billion, a 5% year-over-year decline, and net profit of CNY 64 million, compared to a net loss of CNY 21 million in the same period last year. Both figures missed Goldman Sachs' expectations (revenue expectation: CNY 2.502 billion; net profit expectation: CNY 86 million). The company attributed the decline in both its In Vitro Diagnostics (IVD) distribution and ICL businesses to negative impacts from price reductions. Business Outlook and Drivers: Despite the weak Q1 performance, the company expects ICL business revenue growth to turn positive in Q2 2026 as testing volumes recover and industry concentration increases. For the IVD distribution business, the company forecasts a low single-digit revenue decline for the full year. Notably, while the AI business still represents a small portion of total revenue, it is growing very rapidly. The company stated that gross margins are expected to improve slightly further in 2025, building on previous improvements driven by enhanced laboratory personnel and operational efficiency. Valuation Adjustment and Rating Logic: Given the slower-than-expected recovery of the ICL business, Goldman Sachs has revised its financial model. The new 12-month target price is CNY 18 (previously CNY 19), implying approximately 7.6% downside. Goldman Sachs believes that the potential for AI applications in diagnostics and laboratory operations is significant, offering both incremental revenue and structural cost savings. However, as these medium-term growth prospects are largely reflected in the current share price, the Neutral rating is maintained.

Analysis framework

Goldman Sachs employs a Sum-of-the-Parts (SOTP) valuation method for Dian Diagnostics, separating its business into mature and emerging segments for individual assessment. For the mature ICL and IVD businesses, a 5-year exit P/E method is used, referencing a global peer P/E multiple of 20.7x and applying a 9.5% discount rate. For the early-stage AI business, a two-stage DCF (Discounted Cash Flow) model is applied, assuming a 9.5% discount rate and a 3% perpetual growth rate. This differentiated approach aims to more accurately reflect the risk profiles and growth stages of different business segments. Additionally, the report incorporates Goldman Sachs' proprietary Factor Profile analysis, comparing the company's performance against the market and peers across dimensions such as growth, financial returns, and valuation multiples.

Methodology notes

• Valuation MethodSOTP Sum-of-the-Parts

  SOTP Valuation Method

  Separates a company's different business segments (e.g., mature ICL/IVD businesses and high-growth AI business), applies different valuation models (such as P/E or DCF) to each, and sums the results to address distortions caused by using a single valuation metric for diversified companies.

• Valuation MethodDCF Discounted Cash Flow

  Two-Stage DCF Model

  Used to evaluate high-growth or non-profitable AI businesses by forecasting future free cash flows and discounting them to present value, better reflecting long-term growth potential rather than short-term earnings volatility.

• Industry/Sector Analysis Framework

  Volume-Price Split and Industry Concentration Analysis

  In analyzing the ICL business recovery, this framework distinguishes between the impact of 'testing volume recovery' (volume) and 'price reduction factors' (price), noting that increased industry concentration helps leading players gain market share, a common analytical logic in the healthcare services sector.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Dian Diagnostics (300244.SS)

  Covered target; target price lowered due to Q1 earnings miss and slowing ICL recovery

  Strengths

  China's second-largest ICL service provider; rapid growth in AI business; improved gross margins driven by operational efficiency gains

  Weaknesses

  IVD distribution and ICL businesses dragged down by price reductions; accounts receivable impairment risks; Q1 performance missed targets

  Risks

  Intensified industry competition, significant drop in testing item prices, higher-than-expected accounts receivable impairment, implementation of VBP in the IVD industry

Key data

• 2026Q1 RevenueCNY 2.247 billionDown 5% YoY, below Goldman Sachs' expectation of CNY 2.502 billion
• 2026Q1 Net ProfitCNY 64 millionCompared to a net loss of CNY 21 million in the same period last year; below Goldman Sachs' expectation of CNY 86 million
• New Target PriceCNY 18Lowered from previous CNY 19, based on SOTP valuation
• 2026E Revenue ForecastCNY 10.602 billionDown 6.4% from the old forecast of CNY 11.327 billion
• 2026E Earnings Per Share (EPS)CNY 0.58Down 7.0% from the old forecast of CNY 0.62

Impact & implications

The research report suggests that the earnings miss and target price cut reflect market concerns regarding margin compression and accounts receivable risks in the post-pandemic era. Although the AI business shows signs of scaling, its contribution to overall performance still requires time to validate. For investors, short-term focus should be on how the company manages price pressures and accounts receivable. In the medium to long term, a successful ramp-up of self-developed products or faster-than-expected commercialization of AI diagnostic solutions could serve as upside catalysts; conversely, intensified industry competition or more aggressive implementation of IVD volume-based procurement (VBP) policies could pose downside risks.

Risks

• Intensified industry competition
• Significant drop in testing item prices
• Higher-than-expected accounts receivable impairment
• Implementation of Volume-Based Procurement (VBP) in the IVD industry

What to watch

• Ramp-up speed of self-developed products
• New Volume-Based Procurement (VBP) policies in the IVD industry
• Commercialization progress of AI-enabled diagnostic solutions